关于天境生物与美国硅谷银行无任何业务往来的声明
In light of the recent development of the Silicon Valley Bank (the “SVB”), I-Mab (the “Company”) today issued a statement confirming that the Company does not hold any cash deposits at SVB or its affiliates, and has no exposure to or business dealings with SVB or its affiliates.
鉴于近期美国硅谷银行（Silicon Valley Bank，或SVB）的相关进展，天境生物（“公司”）特此声明，公司与美国硅谷银行或其关联公司无业务合作，在美国硅谷银行或其关联公司亦无任何存款。
About I-Mab
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company’s mission is to bring transformational medicines to patients around the world through innovation. I-Mab’s innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company’s Fast-to-Proof-of-Concept and Fast-to-Market development strategies through internal R&D and global partnerships and commercial partnerships. I-Mab has established its global footprint in Shanghai, Beijing, Hangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit https://www.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.
关于天境生物
天境生物（纳斯达克股票代码：IMAB）是一家充满活力的国际生物科技公司，聚焦肿瘤免疫和自体免疫领域创新或高度差异化生物药的研发、生产和商业化。公司以“持续开发创新生物药，真正改变患者生活”为使命，在“快速产品上市”和“快速概念验证”的双轮策略驱动下，通过自主研发、全球授权合作和商业化合作等多元化模式，迅速建立起拥有超过10个创新药研发管线。公司在上海（总部）、北京、杭州、丽水、香港均设有办公室，并在美国马里兰州和加州圣迭戈设有研发中心并形成美国研发总部。更多信息请访问 http://ir.i-mabbiopharma.com 并关注天境生物领英、推特及微信官方账号。